At a recent event researcher and founder of Bit.bio, Prof. Mark Kotter, Babraham Research Campus in Cambridge/UK, was asked what healthcare looks like in 2050. He gave a twofold answer, that it will be driven by data, but also will be personalised. Mark Kotter elaborates here in more detail what is needed to unlock a healthcare of tomorrow.
Shock: Adrenomed AG gets FDA fast track designation
Latest NewsGerman AdrenoMed AG has got FDA Fast Track designation for its targeted septic shock medicine enibarcimab that restores endothel integrity.
Lonza AG enters R&D collaboration with NeuroSense Therapeutics Ltd
Latest NewsALS specialist NeuroSense Therapeutics Ltd announces it will be collaborating with Swiss Lonza AG to identify exosome-based biomarkers to advance theranostics in neurodegeneration.
Lonza AG enters R&D collaboration with NeuroSense Therapeutics Ltd
Latest NewsALS specialist NeuroSense Therapeutics Ltd announces it will be collaborating with Swiss Lonza AG to identify exosome-based biomarkers to advance theranostics in neurodegeneration.
Essential Pharma acquires Renaissance Pharma Ltd
Latest NewsEssential Pharma has acquired Renaissance Pharma Ltd to commercialise the company’s Phase II program Hu14.18K322A in pedriatric high-risk neuroblastoma.
Unitaid awards Medincell US$6m to fight malaria
Latest NewsGlobal health agency Unitaid has awarded French Medincell Corp (Jacou) an extension grant of up to US$ 6 million over three years to fund thesatety testing of its malaria vaccine mdc-STM.
Genmab broadens ADC pipeline with $1.8bn acquisition of ProfoundBio
Latest NewsGenmab announced today that it will acquire privately held biotech company ProfoundBio for $1.8bn in cash. The deal is designed to help the Danish pharmaceutical company deepen its cancer pipeline with next-generation antibody-drug conjugate therapies where the company has already an inlicensing deal with former Synaffix´s ADC technology platform (which was acquired mid of 2023 by Lonza).
TME Pharma gets FDA Fast Track for Glioblastoma
Latest NewsTME Pharma (France/Germany) announced that the US Food and Drug Administration (FDA) has granted Fast Track designation for NOX-A12 (olaptesed pegol), TME Pharma’s CXCL12 inhibitor, in combination with radiotherapy and bevacizumab for use in the treatment of the aggressive adult brain cancer glioblastoma.
Biology as Software
BackgroundAt a recent event researcher and founder of Bit.bio, Prof. Mark Kotter, Babraham Research Campus in Cambridge/UK, was asked what healthcare looks like in 2050. He gave a twofold answer, that it will be driven by data, but also will be personalised. Mark Kotter elaborates here in more detail what is needed to unlock a healthcare of tomorrow.
Chemspec Europe 2024
Sponsored PublicationsConnect with the world of fine and speciality chemicals: taking place from 19-20 June 2024 at the Messe Düsseldorf exhibition centre in Germany, Chemspec Europe is the key marketplace to showcase the full array of fine and speciality chemicals, bespoke solutions, services, and equipment.
Forbion participates in US financing rounds
Latest NewsForbion, the European life sciences venture capital firm from The Netherlands, announced its participation in oversubscribed Series B financing in Capstan Therapeutics Inc. and Engrail Therapeutics. Both companies are located in San Diego, USA.